Navigation Links
Clinicians Ordering Inappropriate Prostate Screenings

According to a report in the July 9 issue of Archives of Internal Medicine, one of the JAMA/Archives journals , Prostate-specific antigen (PSA) tests to screen for prostate cancer are frequently performed among patients for whom the PSA test is not shown to be beneficial, and clinicians with certain characteristics are more likely to order such inappropriate screening tests.

Most guidelines for clinical practice do not recommend routine PSA screening for men younger than 40, older than 75 or who are expected to live less than 10 years, according to background information in the article.

To our knowledge, there is currently no solid evidence that PSA screening provides any health benefits for these patient populations, the authors write.

Rather, it imposes substantial psychological and financial costs and may lead to diagnostic and therapeutic procedures of questionable benefit.

Because the ultimate decision to perform PSA testing rests with the clinician, it is likely that demographic and other characteristics of physicians, nurses and physician assistants may influence inappropriate screening behaviors.

B. Price Kerfoot, M.D., Ed.M., of the Veterans Affairs Boston Healthcare System and Harvard Medical School, Boston, and colleagues analyzed data from 105,765 male patients who were treated at Veterans Health Affairs (VHA) facilities in New England from 1997 to 2004. Information about the patients and the 1,552 health care clinicians who ordered PSA tests was gathered from VHA databases.

Inappropriate screening was defined as PSA testing in patients older than 75 or younger than 40 who had not been diagnosed with prostate cancer, were not taking prostate cancerspecific medications or had not undergone related procedures.

Of the 232,302 PSA tests ordered during the study period, 37,483 (16.1 percent) were considered inappropriate, with 35,612 (15.3 percent) performed in patients older than 75 years and 1,871 (0.8 percent) in patients younger than 40 years.

Of the health care clinicians who ordered inappropriate tests, 51.3 percent were male, 79.4 percent were physicians, 53.4 percent were trainee physicians and 8.2 percent were urologists.

Practitioners who were urology specialists, male, infrequent PSA tests orderers and affiliated with specific hospitals had significantly higher levels of inappropriate PSA screening. Compared with attending physicians, nurses and physician assistants had significantly lower levels of inappropriate screening, the authors write.

The percentage of inappropriate PSA screening increased significantly with the age of male health care providers, they continue.

The cause of these sex and age differences is not clear. It is possible that, as they age, male health care providers increasingly empathize with their older male patients over prostate cancer concerns. Their prostatemphathy may then lead to more aggressive screening in these older male patients.

Patient education and systems-level changes, such as a computerized system that could alert clinicians when they attempt to order an inappropriate PSA test, could help reduce the level of PSA screening misuse, the authors conclude.

For more information, contact JAMA/Archives Media Relations at 312/464-JAMA (5262) or e-mail mediarelations@jama-archives.org


'"/>




Related medicine news :

1. Clinicians Participating In the Pharmaceutical-Sponsored Trails Tend To Prescribe Their Drugs
2. More Elderly Take Inappropriate and Harmful Medications
3. Does Your Prescription Have An Inappropriate Medicine?
4. Elders in Scotland Inappropriately Charged For Free Food
5. Studies Reveal Inappropriate Use Of Drug-Coated Stents
6. Cancer Doctors Okays Controversial Prostate Therapy
7. Radioactive Seeds used in Prostate Cancer treatment can migrate with the body
8. New Prostate Cancer Vaccine Shows Promise
9. Hormone Therapy applicable for Prostate Cancer
10. Prostate cancer and Vitamins
11. Response to chemotherapy could be measured by Prostate-Specific Antigen Doubling Time
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/27/2016)... ... June 27, 2016 , ... ... technology to revolutionize the emergency ambulance transport experience for the millions of people ... how Uber has disrupted the taxi industry through the use of technology. Now, ...
(Date:6/26/2016)... ... June 26, 2016 , ... On June 10-11, 2016, A ... 2016 Cereal Festival and World’s Longest Breakfast Table in Battle Creek, MI, where the ... history as home to some of the world’s leading providers of cereal and other ...
(Date:6/26/2016)... ... , ... Brent Kasmer, a legally blind and certified personal trainer is helping to develop a ... fitness app plans to fix the two major problems leading the fitness industry today:, ... type program , They don’t eliminate all the reasons people quit their exercise ...
(Date:6/25/2016)... ... 25, 2016 , ... Austin residents seeking Mohs surgery services, can now turn ... to Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization ... selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction ...
(Date:6/25/2016)... ... , ... First Choice Emergency Room , the largest network of independent ... Director of its new Mesquite-Samuell Farm facility. , “We are pleased to announce ... Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 2016   Pulmatrix, Inc ., (NASDAQ: ... drugs, announced today that it was added to the ... its comprehensive set of U.S. and global equity indexes ... important milestone for Pulmatrix," said Chief Executive Officer ... our progress in developing drugs for crucial unmet medical ...
(Date:6/23/2016)... -- Any dentist who has made an implant supported denture ... of them do not even offer this as a viable ... costs involved. And those who ARE able to offer that ... cost that the majority of today,s patients would not be ... , founder of Dental Evolutions Inc. and inventor of Implanova ...
(Date:6/23/2016)... Capricor Therapeutics, Inc. ... company focused on the discovery, development and commercialization ... in its ongoing randomized HOPE-Duchenne clinical trial (Halt ... its 24-patient target. Capricor expects the trial to ... 2016, and to report top line data from ...
Breaking Medicine Technology: